-
Tumor-activated Prodrug and Tumor-targeting Technologies: ADEPT, GDEPT and PDEPT to Increase Drug Efficacy and Reduce Drug Toxicity
Wednesday, November 14
2:00 pm – 4:00 pm
Roundtable
ACPE #073-999-07-555-L04
Adjuvant chemotherapy is one of the common treatment modalities for cancers. Tremendous effort is being extended to improve the efficacy of chemotherapy with a limited success. A delicate dose regimen is usually required to balance drug effect, toxicity, and resistance. The selective activation of prodrugs in tumors by exogenous enzymes will increase drug’s efficacy, decrease drug’s toxicity, and overcome drug resistance. The targeted prodrug therapy can be accomplished by technologies including antibody-directed enzyme prodrug therapy (ADEPT), gene-directed enzyme prodrug therapy (GDEPT), and polymer-directed enzyme prodrug therapy (PDEPT). The central part of technologies is to deliver functional enzyme or drug-activating enzyme gene to tumor tissues, followed by systemic administration of a prodrug. This roundtable will focus on advantages and disadvantages associated with each technology and future perspective for current approaches.
Moderators
Jarkko T. Rautio, Ph.D.
University of Kuopio
Duxin Sun, Ph.D.
Ohio State University
Potent Antibody-drug Conjugates for Cancer Therapy
Peter Senter, Ph.D.
Seattle Genetics
Cytochrome P450 Prodrug Activitation Gene Therapy for Cancer
David Waxman, Ph.D.
Boston University
Vascular Targeting Antibody Conjugates for the Therapy of Cancer and of Chronic Inflammatory Diseases
Dario Neri, Ph.D.
Institute of Pharmaceutical Sciences